GLP-1 Medications: Benefits, Options & Genetic Insights

Last reviewed: May 21, 2026

Last updated: May 21, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

GLP-1 receptor agonists are a class of medications that activate glucagon-like peptide-1 receptors, regulating appetite and blood glucose levels. Clinical data shows GLP-1 medications have demonstrated weight loss and cardiovascular benefits in multiple randomized controlled trials, with semaglutide showing approximately 15% body weight reduction over 68 weeks in the STEP trials and tirzepatide demonstrating up to 22% reduction in the SURMOUNT trials.

Beyond standard medication options, understanding your genetic predispositions in peptide pathways may provide valuable context for provider conversations. PlexusDx uses licensed 503A compounding pharmacies to provide access to compounded GLP-1 medications alongside precision genetic testing, enabling a more personalized approach than one-size-fits-all prescribing.

The GLP-1 Medication Class: Mechanism and Clinical Purpose

GLP-1 receptor agonists mimic the glucagon-like peptide-1 hormone, which signals satiety to the brain and slows gastric emptying. This dual action addresses appetite regulation and metabolic control, distinguishing GLP-1s from older weight management or diabetes medications that relied on different physiological pathways.

Originally developed for type 2 diabetes management, GLP-1 medications have expanded into broader metabolic wellness due to demonstrated cardiovascular safety and weight loss efficacy. Major cardiovascular outcome trials, including LEADER (liraglutide) and PIONEER (semaglutide oral), showed reduced cardiovascular events in patients with diabetes or obesity-related conditions.

Comparing Injectable and Oral GLP-1 Options: Administration and Evidence

GLP-1 medications are available in two primary delivery formats: weekly subcutaneous injections and daily oral tablets. Each format has distinct pharmacokinetics, adherence profiles, and clinical evidence supporting their efficacy. Your provider may recommend one format over another based on your medical history, preference, and treatment goals.

Medication Type	Delivery Method	Dosing Schedule	Key Clinical Evidence
Semaglutide (compounded)	Subcutaneous injection or oral	Weekly injection or daily oral tablet	STEP trials: ~15% weight loss; cardiovascular benefit in SUSTAIN-6
Tirzepatide (compounded)	Subcutaneous injection or oral	Weekly injection or daily oral tablet	SURMOUNT trials: up to 22% weight loss; dual GLP-1/GIP receptor action
Liraglutide	Daily subcutaneous injection	Once daily	LEADER trial: cardiovascular safety; approximately 5-8% weight loss
Dulaglutide	Subcutaneous injection	Once weekly	REWIND trial: cardiovascular protection; moderate weight loss effect

GLP-1 Efficacy Variability: Why Genetic Predispositions May Matter

Clinical data shows considerable variability in individual GLP-1 response—some patients achieve 20%+ weight loss while others see more modest results. This variation stems partly from differences in GLP-1 receptor expression, metabolic capacity, and genetic predispositions in peptide signaling pathways. Understanding your genetic background may help contextualize expected outcomes.

Key genetic variants such as GLP1R rs6923761, GIPR rs1800437, and MC4R rs17782313 influence how your body's GLP-1 and GIP signaling systems function. While genetic predispositions do not predict exact medication response, they may provide providers with additional information to support treatment selection and goal-setting conversations.

Safety Considerations and Who Should Evaluate GLP-1 Treatment

GLP-1 medications are contraindicated in personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2. Nausea, vomiting, and gastrointestinal disturbances are common early side effects, typically dose-dependent and often transient. Serious but rare adverse events include pancreatitis and gallbladder complications; immediate medical attention is warranted if severe abdominal pain develops.

Appropriate candidates for GLP-1 therapy include adults with type 2 diabetes, obesity-related conditions, or cardiovascular risk factors, as determined by qualified healthcare providers. Compounded GLP-1 access through PlexusDx requires a valid prescription and medical consultation. Your provider should evaluate your full medical history, current medications, and treatment goals before initiating therapy.

How PlexusDx Supports a More Personalized Approach

PlexusDx's Precision Peptide Genetic Test may help provide context around your genetic predispositions in GLP-1 and GIP receptor pathways. The test screens variants including GLP1R rs6923761, GIPR rs1800437, FTO rs9939609, and MC4R rs17782313—regions that influence metabolic regulation and appetite signaling. This information should be interpreted with a qualified healthcare provider as part of a comprehensive treatment discussion.

Understanding your peptide genetic predispositions does not predict your exact medication response or guarantee specific weight loss outcomes. Instead, genetic insights may help providers recognize patterns in your metabolic biology and tailor counseling around realistic expectations, dosing strategies, and potential side effect tolerance. The Precision Peptide Genetic Test ($99 add-on or $298 standalone) is available alongside all PlexusDx compounded GLP-1 and tirzepatide offerings.

When combined with a provider consultation, genetic predisposition data can support a more informed, precision-guided conversation about which compounded GLP-1 option—injectable semaglutide, oral semaglutide, compounded tirzepatide injection, or oral tirzepatide—aligns best with your individual biology and health objectives. PlexusDx's licensed 503A compounding pharmacies ensure quality and consistency for all compounded peptide medications.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Oral starts at $279/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.